Stay updated with breaking news from Corp Communication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KUALA LUMPUR, Feb 27 — The Ministry of Science, Technology and Innovation (Mosti) will embark on a groundbreaking data-sharing initiative with the Malaysia Technology Expo...
"The US is a superpower, a largest market. Specifically, there are businesses or sectors which are not present at that scale in any other country apart from the US. If you want to buy technology, innovative health care businesses which are there in the US, you have to go to the US market as a part of your diversification strategy."
Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate … Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (...
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO of Mydecine, stated, “The Board of Directors welcomes Ms. Josephine Wu … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a...
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange . Final approval is subject to the Company fulfilling all of NEO’s listing requirements. With the impending … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Compa...